Model Organisms: A Precious Resource for the Understanding of Molecular Mechanisms Underlying Human Physiology and Disease
- 1Institute of Molecular Biology and Pathology, National Research Council (CNR), Italy
- 2Department of Biotechnology and Biosciences, School of Science, University of Milano-Bicocca, Italy
This issue includes 8 reviews and 5 research articles, which highlight how research in model organisms lays the foundations for the comprehension of molecular mechanisms underlying human diseases. Although budding yeast and humans are separated by a billion years of evolutionary history, more than 400 essential yeast genes can be replaced with their human orthologs. Pioneering genetic studies in yeast have contributed to understand the mechanisms involved in autophagy and vesicle trafficking, two processes involved in cancer and neurodegenerative disorders (Takeshige et al; 1992; Mizushima et al., 1998; Novick et al., 1980). More recently, production of yeast strains expressing human genes (“humanized yeast”) has been essential for the detailed analysis of normal and pathogenic variants (Laurent et al., 2016). Drosophila melanogaster provides an extremely valid resource to investigate the mechanisms involved in organ formation and in the pathology of human diseases. Nearly 65% of human genes have orthologs in Drosophila melanogaster and nearly 75% of the genes involved in human disease have functional orthologs in flies (Reiter et al., 2001; Chien et al., 2002). The sophisticated genetic tools offered by Drosophila allow rapid generation of models for human disease, assaying the functional effects of human variant alleles and testing new therapeutic drugs (Moulton and Letsou, 2016; Wangler et al., 2017). Danio rerio shares vertebrate-conserved characteristics with human including very similar organs and is a highly suitable model system for investigating gene functions involved in hematopoiesis and screening for novel potential drugs (Wangler et al., 2017). Mouse models of human diseases are the most commonly used, reflecting the genetic and physiological similarities between humans and mice (Perlman, 2016).
Using budding yeast to study the molecular pathways that are altered in human diseases
Orlandi and coauthors (2018) used yeast as a model system to study aging of post-mitotic mammalian cells. Their data describe a connection between Nicotinamide Adenine Dinucleotide (NAD+) content, mitochondrial functionality and chronological life span. They show that, during chronological aging, an altered expression of the specific mitochondrial NAD+ carriers deeply influences the metabolic reprogramming that enables cells to acquire features required to maintain viability during aging.
Ohkuni and coauthors (2018) used yeast as a cellular model of neurodegenerative disorders such as Huntington’s Disease (HD). They show that the SUMO-targeted ubiquitin ligase (STUbL) Slx5 reduces the toxicity and abnormal transcriptional activity associated with a mutant fragment of Huntingtin (Htt) that induces aggregation, the causative agent of HD. Importantly RNF4, the human ortholog of Slx5, limits the aberrant transcriptional activity of aggregation-prone Htt in yeast and in several cultured human cell lines. Thus, this study uncovers a conserved pathway that counteracts the accumulation of aggregating, transcriptionally active Htt, on chromatin in both yeast and in mammalian cells.
Fraschini’s review is focused on the molecular pathways and proteins involved in the control mitotic spindle morphogenesis and function, that are highly conserved from yeast to humans and whose impairment is connected with the development of human diseases. Fraschini illustrates the processes of spindle formation and orientation in yeast and in humans and includes many examples of misregulation that lead to the development of cancer and other human diseases (Fraschini, 2019).
Smurova and collaborators (2018) report the role of centromeres and kinetochores in preserving genetic stability, in particular they describe how centromere transcription contributes to faithful kinetochore function, how pericentromeric chromatin is silenced by RNA processing and the transcriptional misregulation of (peri)centromeres during stress, natural aging and disease.
Bonetti and coauthors (2018) illustrate how DNA ends are processed in budding yeast in order to maintain genome stability. DNA double-strand breaks (DSBs) are dangerous lesions that can be repaired by homologous recombination (HR) that occurs after DNA ends are correctly processed by several nucleases by a process called DNA end resection. The same nucleases function also during DNA replication in the processing of replication fork structures. The authors describe current knowledge of the mechanism of resection at DNA DSBs and replication forks.
Natali and Rancati (2019) describe the mutator phenotype in budding yeast. The mutator phenotype enhances genome instability and generation of phenotypic variation in a population of cells and increases the probability that some of these variations undergo selection and clonal expansion in challenging environments. This issue is particularly relevant for human health since cancer cells experience an increased mutational charge during early steps of carcinogenesis. The authors discuss the activity of the DNA replication and repair machineries and how mutations can confer increased genome instability. In addition, they describe recent clinical evidences in cancer biology indicating that these lessons can be applied to tumor development.
Using model organisms to model tumor formation and progression
Sollazzo and coauthors (2018) used Drosophila larval wing epithelium to investigate the impact of MYC upregulation on cells carrying mutations in neoplastic tumor suppressor genes (nTSGs). MYC overexpression confers to cells mutant for different nTSGs, the ability to initiate multifocal, three-dimensional growth, a hallmark of mammalian pre-cancerous fields.
By using three different models of Ras-induction and tumor formation in zebrafish, Anelli and coauthors (2018) demonstrate that six microRNAs increase following expression of a constitutively active HRASG12V allele. Two Ras-induced microRNAs, namely miR-146a and miR93a, target the Jmjd6 gene, which encodes a jumonjiC domain protein. Results in this study show that Jmjd6 plays a critical role in zebrafish melanoma development and that miR-146a and miR93a function as tumor suppressors, antagonizing Jmjd6 activation.
Mirzoyan and coauthors (2019) provide a comprehensive insight into the signaling pathways involved in tumorigenesis that are conserved in flies and highlight the ease to genetically manipulate these circuits to study cancer biology. In addition they describe examples of Drosophila cancer models and their use to identify new therapeutic strategies.
Merigliano and coauthors (2018) describe the link between vitamin B6, diabetes and cancer. Although several data indicate that diabetes and cancer are correlated, the molecular mechanisms involved remain to be clarified. Recent results obtained in Drosophila indicate that vitamin B6 deficiency causes hyperglycemia and increases DNA damage. These data suggest that in diabetic patients high PLP levels should increase the frequency of DNA damage thus contributing to cancer formation and progression.
Using model organisms to study the neurological defects associated with human diseases.
Burla and coauthors (2018) demonstrate that mutant mice with progeroid traits, caused by reduced expression of the Ft1 gene (the ortholog of human AKTIP), display repeated seizures not linked to overt brain morphological alterations or severe neurodegeneration. However Ft1 reduction is associated with the activation of the inflammatory markers IL-6 and TGF-β. Remarkably reduction of the guardian of the genome p53 rescue the epileptic behavior and reverse back the expression of IL-6 and TGF-β in Ft1 mutant mice, suggesting an involvement of DNA damage response in these phenotypes.
Two reviews describe the use of Drosophila melanogaster for dissecting the molecular mechanisms underlying the neurological defects in inherited human diseases. Congenital disorders of glycosylation (CDGs) are multisystemic diseases caused by mutations in genes controlling the glycosylation pathways (Freeze et al., 2015). Most CDGs are associated with neurological defects, including mental retardation and seizures. As described by Frappaolo et al. (2018) Drosophila melanogaster is emerging as a well-suited model organism for modeling Congenital Disorders of N-linked glycoprotein glycosylation due to a well-characterized glycome and a plethora of electrophysiological and behavioral assays that can be used to test neurological alterations in the whole organism.
The Fragile-X (Fra-X) Syndrome, caused by mutations in the Fragile-X Mental Retardation (Fmr1) is associated with intellectual disability, autism, hyperactivity and language delay, long face and large ears, macroorchidism and irregular spermatids (Santoro et al., 2012). The Drosophila Fra-X disease model recapitulates many phenotypic aspects of the Fra-X syndrome including defective neuronal architecture and synaptic function and altered germline development. Specchia et al. (2019) describe the involvement of dFmr1/FMRP protein in the piRNA pathway and in the DNA genome response, which may open up new perspectives in the search of potential therapeutic targets.
Keywords: Model orgainsms, human diseases, Human physiological model, DNA Damage, Human disorders
Received: 05 Jul 2019;
Accepted: 08 Aug 2019.
Copyright: © 2019 Giansanti and Fraschini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Dr. Maria Grazia Giansanti, Institute of Molecular Biology and Pathology, National Research Council (CNR), Rome, Italy, firstname.lastname@example.org
Dr. Roberta Fraschini, Department of Biotechnology and Biosciences, School of Science, University of Milano-Bicocca, Milano, Italy, email@example.com